当前位置: X-MOL首页SCI期刊查询及投稿分析系统 › npj Vaccines杂志
npj Vaccines
基本信息
期刊名称 npj Vaccines
NPJ VACCINES
期刊ISSN 2059-0105
期刊官方网站 http://www.nature.com/npjvaccines
是否OA Yes
出版商 Nature Publishing Group
出版周期
文章处理费 登录后查看
始发年份 2016
年文章数 173
影响因子 6.9(2023)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学2区 IMMUNOLOGY 免疫学3区
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验2区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 11.9 2.127 1.170
Medicine
Pharmacology (medical)
12/272 95%
Pharmacology, Toxicology and Pharmaceutics
Pharmacology
27/313 91%
Medicine
Infectious Diseases
35/344 89%
Immunology and Microbiology
Immunology
39/236 83%
补充信息
自引率 4.3%
H-index 8
SCI收录状况 Science Citation Index Expanded
官方审稿时间 登录后查看
网友分享审稿时间 数据统计中,敬请期待。
接受率 登录后查看
PubMed Central (PMC) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2059-0105%5BISSN%5D
投稿指南
期刊投稿网址 https://mts-npjvaccines.nature.com/cgi-bin/main.plex
收稿范围
npj Vaccines considers all aspects of research covering the development of human and veterinary vaccines.

The journal covers a broad range of topics including but not limited to:

    Vaccine development and design
    Vaccine immunology and mechanisms of action
    Vaccine adjuvants and delivery systems
    Vaccine safety and efficacy evaluation
    Vaccine production and manufacturing
    Vaccine hesitancy and acceptance
    Vaccines for emerging infectious diseases
    One Health approaches to vaccination
    Vaccines for non-infectious diseases, including cancer vaccines, and against chronic conditions, autoimmune diseases, allergies, and non-communicable diseases
    Veterinary vaccines for animal health
    Vaccine policy, regulation, and access

The journal offers more choice to Nature Portfolio authors who are seeking a fully open-access and more inclusive platform for publishing their work. The journal is led by vaccine experts who collaborate to cultivate high-quality research. As part of the npj Series, this journal focuses on fostering global partnerships with the research community and other Springer Nature journals.
收录体裁
Article 
Brief Communication 
Case Report 
Comment 
Editorial 
Matters Arising 
Meeting Report 
Perspective 
Protocol 
Review
投稿指南 https://www.nature.com/npjvaccines/for-authors-and-referees
投稿模板
参考文献格式 https://endnote.com/downloads/styles/
编辑信息

Editor-in-Chief

Alan D. T. Barrett, PhD

Director, Sealy Institute for Vaccine Sciences

University of Texas Medical Branch

TX, USA 

 

Alan D.T. Barrett obtained his B.S., M.S. and PhD in the area of virology from the University of Warwick, followed by a post-doctoral fellowship in arbovirology at the London School of Hygiene and Tropical Medicine. He is currently Director of the Sealy Institute for Vaccine Sciences and the World Health Organization Collaborating Center for Vaccine Research, Evaluating and Training for Emerging Infectious Diseases. He is a Professor in the Departments of Pathology and Microbiology & Immunology at University of Texas, Medical Branch (UTMB). Dr. Barrett is a leading expert in the fields of vaccine development for flaviviruses. His lab is undertaking basic research and preclinical development for vaccines against various flavivirus diseases. He has made several contributions to World Health Organization activities on vaccine research, development and implementation. He is a member of the Scientific Advisory Committee, Coalition for Epidemic Preparedness Innovations (CEPI) that is developing vaccines for Ebola, Nipah, Lassa fever and MERS, the flavivirus vaccine working group of the CDC Advisory Committee on Immunization Practices and has served on many NIH study sections.

 

Associate Editors

Paul A. MacAry, PhD

Director, LSI Immunology Programme

National University of Singapore

Singapore, Singapore

 

 

Associate Professor Paul MacAry received his BSc (Hons) in Molecular Genetics from Glasgow University in 1993 and his PhD in Immunology from GKT, University of London in 1998. He performed post-doctoral researches in the Cambridge University Institute for Medical Research (CIMR) and since 2005 has been an independent investigator in the Department of Microbiology and Immunology program at the National University of Singapore (NUS). The multi-disciplinary research in his laboratory covers the entire spectrum of scientific endeavour, from basic research to industrial applications with an emphasis on antibody biology, immune repertoire mapping and protein engineering applications in infectious diseases. Professor MacAry was a founding member and Meetings Secretary for the Singaporean Society of Immunology (SSI) — Singapore’s first international learned society — and the founding scientist for two biotechnology companies, BSCR LTD founded in Cambridge in 2004 and Antibody Cradle LTD founded in Singapore in 2012.

 

Pei-Yong Shi, PhD

I.H. Kempner Professor of Human Genetics

University of Texas Medical Branch

TX, USA 

 

 

Along with his post at UTMB, Pei-Yong Shi serves as adjunct Professor of Emerging Infectious Diseases at the Duke-NUS Graduate Medical School in Singapore and Honorary Professor at the Wuhan Institute of Virology, Chinese Academy of Sciences. He studies flaviviruses and develops antivirals and vaccines. He received his PhD from Georgia State University. After postdoctoral training at Yale, he joined Bristol-Myers Squibb to develop antiviral drugs and New York State Department of Health to study emerging viral diseases. From 2008 to 2015, he served as Executive Director to lead drug discovery at Novartis Institute for Tropical Diseases. His group developed the first infectious clones of the epidemic strain of West Nile and Zika viruses, discovered two cap methylation activities of flavivirus NS5 protein, identified essential RNA elements for flavivirus replication, established various platforms for flavivirus vaccine and drug discovery and pioneered therapeutics development for dengue virus.

 

Richard Titball, DsC, PhD

Professor of Molecular Microbiology 

University of Exeter

Exeter, United Kingdom 

 

 

Prof. Titball has worked extensively on a range of bacterial pathogens including Burkholderia pseudomallei, Francisella tularensis, Yersinia pestis, Campylobacter jejuni and Clostridium perfringens originally at the Defence Science and Technology Laboratory and more recently at the University of Exeter where he is Professor of Molecular Microbiology. His past work has provided new insight into the molecular architectures and mode of action of bacterial toxins and he led initiatives to sequence and exploit the first genomes of a range of candidate biothreat agents. Prof. Titball’s work also resulted in the development of vaccines against plague and C. perfringens toxins which have been trialled in humans and in animals, respectively. His principal interests now lie with understanding the molecular basis of disease caused by B. pseudomallei and C. perfringens and the development of vaccines against disease caused by these pathogens.

 

Veronika von Messling, Dr. med. vet.

 

Director General, Life Sciences

Federal Ministry of Education and Research

Berlin, Germany

 

 

Prof.  Dr. Veronika von Messling is Director General of Life Sciences at the Federal Ministry of Education and Research in Germany.  She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany.  After postdoctoral training at Mayo Clinic in Rochester, MN, she was an Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore. Her research interest lies in characterizing the pathogenesis of respiratory viruses to develop novel prophylactic and therapeutic strategies. Dr. von Messling has been awarded various awards and prizes such as the Chercheur-boursier senior Award, FRSQ, (2011), and the Löffler-Frosch Prize, German Society of Virology (2011). She is also a member of various societies such as the European Society of Virology, Canadian Society of Microbiology and Deutsche virologische Gesellschaft.

 

David H. Walker, MD, PhD

Department of Pathology

University of Texas Medical Branch

TX, USA

 

 

David Walker is the Director of the Center for Biodefense and Emerging Infectious Diseases, and Professor and former Chairman of the Department of Pathology at the University of Texas Medical Branch at Galveston. He received his M.D. from Vanderbilt University, and then later served as a Research and Clinical Fellow at Harvard University School of Medicine. Dr. Walker’s research has elucidated mechanisms of immunity to Rickettsia and Ehrlichia, developed animal models for investigating rickettsioses and ehrlichioses and contributed to elucidating the pathology and pathophysiology of Lassa fever, Rocky Mountain spotted fever, Mediterranean spotted fever and human monocytotropic ehrlichiosis. Among emerging infections, he contributed to the discovery, characterization and/or epidemiology of Anaplasma phagocytophilum (human granulocytotropic anaplasmosis), Rickettsia japonica (Japanese spotted fever), R. felis (flea-borne spotted fever) and E. chaffeensis (human monocytotropic ehrlichiosis).

 

Editorial Board Members

 

L. Garry Adams — Texas A&M College Station, Texas, USA

Sylvie Alonso — National University of Singapore, Singapore, Singapore

Carl R. Alving — Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

Peter L. Andersen — Statens Serum Institute, Copenhagen, Denmark

Bernard Arulanandam — University of Texas at San Antonio, Texas, USA

David W. C. Beasley — University of Texas Medical Branch, Texas, USA

Martin Beer — Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany

David I. Bernstein — Cincinnati Children's Hospital Medical Center, Ohio, USA

Paul L. Bigliardi — University of Minnesota, Minnesota, USA

Danny Casimiro — Aeras, Maryland, USA

Ashok K. Chopra — University of Texas Medical Branch,Texas, USA

James Crowe — Vanderbilt University, Tennessee, USA

Denise Doolan — James Cook University, Australia

J. Stephen Dumler — Uniformed Services University for the Health Sciences, Maryland, USA

Janice Endsley — University of Texas Medical Branch (UTMB),Texas, USA

Susanna Esposito — Università degli Studi di Milano, Milan, Italy

Ali I. Fattom — NanoBio Corporation, Michigan, USA

Thomas Ficht — Texas A&M University, Texas, USA

Katja Fink — Humabs BioMed SA, Bellinzona, Switzerland

Anthony R. Fooks — Animal and Plant Health Agency (APHA), Surrey, UK

Alexander Freiberg — University of Texas Medical Branch, Texas, USA

Tong-Ming Fu — Merck & Co., Philadelphia, USA

Michael Gale, Jr. — University of Washington, Washington, USA

Adolfo Garcia-Sastre — Mount Sinai School of Medicine New York, USA

Nathalie Garcon — Bioaster Technology Research Institute, Brussels, Belgium

Nisha J. Garg — University of Texas Medical Branch,Texas, USA

Sarah Gilbert — Jenner Institute, University of Oxford, Oxford, UK

Jaap Goudsmit — University of Amsterdam, Amsterdam, Netherlands

Barney S. Graham — NIH, Maryland, USA

Beth-Ann Griswold Coller — Merck Research Laboratories, New Jersey, USA

Joachim Hombach — World Health Organization, Geneva, Switzerland

Tetsuro Ikegami — University of Texas Medical Branch, Texas, USA

Ken J. Ishii — Osaka University, Osaka, Japan

Nicholas Jackson — Sanofi-Pasteur, Lyon, France

Kathrin Jansen — Pfizer Vaccine Research, New York, USA

Stefan Kappe — Seattle Biomedical Research Institute, Washington, USA

David C. Kaslow — PATH, Seattle, Washington, USA

Stephen Kent — University of Melbourne, Melbourne, Australia

Janine Kimpel — Medical University of Innsbruck, Innsbruck, Australia

Dennis M. Klinman — National Cancer Institute, NIH, Maryland, USA

Eiji Konishi — Osaka University, Osaka, Japan

Margaret Liu — Karolinska Institute, Stockholm, Sweden

Shan Lu — University of Massachusetts Medical School, Massachusetts, USA

Mary Marovich — National Institute of Allergy and Infectious Diseases, NIH, Maryland, USA

Peter Mason — Regeneron Pharmaceuticals, Tarrytown, New York, USA

Jere W. McBride — University of Texas Medical Branch,Texas, USA

Philip Minor — National Institute for Biological Standards and Control, Potters Bar, UK

Thomas P. Monath — NewLink Genetics, Iowa, USA

Kathleen M. Neuzil — University of Maryland School of Medicine, Maryland, USA

Walter Orenstein — Emory University, Georgia, USA

Slobodan Paessler — University of Texas Medical Branch, Texas, USA

Guy H. Palmer — Washington State University, Washington, USA

Daniel Paris — Mahidol Oxford Research Unit, Bangkok, Thailand

Kevin Pethe — Nanyang Technological University, Singapore

Stanley Plotkin — University of Pennsylvania, Vaxconsult, Pennsylvania, USA

Maarten Postma — University of Groningen, Groningen, Netherlands

Bali Pulendran — Emory University, Atlanta, Georgia, USA

Cheng-Feng Qin — Beijing Institute of Microbiology and Epidemiology, Beijing, China

Rino Rappuoli — GSK Vaccines, Siena, Italy

Steven G. Reed — Infectious Diseases Research Institute, Washington, USA

Guus Rimmelzwaan — University of Veterinary Medicine, Center for Emerging Infections and Zoonoses, Hanover, Germany

Jai Rudra — Washington University in St. Louis, Missouri, USA

Richard Rupp — University of Texas Medical Branch, Texas, USA

Robert Sauerwein — Radboud University Medical Center, Nijmegen, Netherlands

Alexander Schmidt — GSK Vaccines, Brussels, Belgium

Alessandro Sette — La Jolla Institute for Allergy and Immunology, California, USA

John Shiver — Sanofi-Pasteur Vaccines, Swiftwater, Pennsylvania, USA

Mark K. Slifka — Oregon Health & Science University, Orlando, USA

Jon Smith — PaxVax, Inc., San Diego, CA, USA

Lynn Soong — University of Texas Medical Branch, Texas, USA

J. Erin Staples — Centers for Disease Control, Colorado, USA

Geraldine Taylor — Pirbright Institute, Woking, UK

Dirk Teuwen — Union Chimique Belge (UCB), Brussels, Belgium

Ralph A. Tripp — The UGA college of Veterinary Medicine, Georgia, USA

Takafumi Tsuboi — Ehime University, Ehime, Japan

Sylvia van den Hurk — University of Saskatchewan, Saskatchewan, Canada

Kirsten Vannice — World Health Organization, Geneva, Switzerland

Hengliang Wang — Beijing Institute of Biotechnology, Beijing, China

Scott C. Weaver — University of Texas Medical Branch, Texas, USA

David B. Weiner — University of Pennsylvania, Pennsylvania, USA

Fidel Zavala — John Hopkins Bloomberg School of Public Health, Maryland, USA

Qinjian Zhao — Xiamen University, Xiamen, Fujian, China


我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug